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Scientific Abstracts Results suggested that there were significant differences between two groups for sex, duration of disease, RF and CRP. There was also some evidence of difference between groups in terms of their age and pre-treatment DAS28 score but these differences were only of borderline statistical significance. There was smaller proportion of males in the obese group with 20% male compared to 36% of non-obese patients. Obese patients had on average a longer disease duration with a median of 12 years compared to a median of 8 years for the non-obese group. The RF status also varied between groups with a much higher proportion of patients in the negative category for the obese group. CRP values were significantly lower in the obese group with a median of 24 compared to 35 in the non-obese group. Background: TNF inhibitors have become an important part of healthcare worldwide for inflammatory diseases such as RA 1 . Many publications show that responding patients have higher Adalimumab (Ada) serum trough levels (ATL) than non-responders. These factors are influenced by age, weight, gender or pharmacokinetics, which in turn depend on immunogenicity. Concomitant use of immunomodulators such as methotrexate (MTX) reduces immunogenicity and enhances therapy benefits 1,3 .Increasing drug dosage in patients with less response is the standard practice, while lowering dosage is advisable in patients achieving remission. Many recent publications 2 assess serum trough levels that reflect optimal response and which could be used as benchmark for guidance to implement the Therapeutic Drug Monitoring. Objectives: To establish an optimal Ada serum trough level (ATL) range in RA patients associated with good clinical response. Sixty-five and 72% of patients were RF and ACPA positive, respectively. ATL were similar in patients treated with concomitant MTX (χ=3.82±2.42 μg/ml) or Ada monotherapy (χ=3.54±2.43 μg/ml) p=0.81. Consistent with previous studies 1,2 , low-disease activity patients (DAS28≤3.2) presented higher Ada circulating levels than patients with high-disease activity [3.7 μg/ml (IQR 2.97-5.48) vs. 1.71 μg/ml (IQR 0.23-4.51), p=0.01]. The median of Ada levels excluding the values (n=6) that showed immunogenicity was 3.42 μg/ml (IQR 1.55-5.03) where 3.50 μg/ml represented the most frequent value (15% of patients). Lack of clinical improvement ( DAS<1.2) was linked to drug levels below percentile 25 (p=0.04) whilst Ada levels above percentile 75 did not ensure more clinical improvement (p=0.7) than the values around the median. Conclusions: ATL correlate with the disease activity and with the clinical improvement. The optimal range associated with good therapeutic response after the standard dose is 1.5-5 μg/ml. Higher circulating drug levels do not entail better response, which indicates they could be unnecessary. The knowledge of the optimal drug ranges can guide the Personalized Drug Therapy in order to maximise effectiveness and minimise costs. 
